Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
Year: 2023
Type: conference-abstract
Authors: R.P. Frantz, V.V. McLaughlin, S. Sahay, P. Escribano Subías, R.L. Zolty, R.L. Benza, R.N. Channick, K.M. Chin, A.R. Hemnes, L.S. Howard, O. Sitbon, J.-L. Vachiery, R.T. Zamanian, M. Cravets, R.F. Roscigno, D. Mottola, E. Elman, E. Parsley, R. Aranda, L.S. Zisman, H.-A. Ghofrani, on behalf of the TORREY Study Investigators
Institutions: Mayo Clinic, University of Michigan, Houston Methodist, Weill Cornell Medicine, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, University of Nebraska Medical Center, The Ohio State University Wexner Medical Center, Ronald Reagan UCLA Medical Center, UCLA Medical Center, The University of Texas Southwestern Medical Center, Vanderbilt University, Imperial College Healthcare NHS Trust, Université Paris-Saclay, Bicêtre Hospital, Erasmus Hospital, Stanford Medicine, Stanford University, Gossamer Bio (United States), Justus-Liebig-Universität Gießen
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4367599705